Tris(hydroxymethyl)essigsaeure | 2831-90-5

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: Tris(hydroxymethyl)essigsaeure
• 英文别名: α,α,α-tris(hydroxymethyl)acetic acid；3-hydroxy-2,2-bis(hydroxymethyl)propanoic Acid
• CAS: 2831-90-5
• 化学式: C₅H₁₀O₅
• 分子量: 150.131
• InChiKey: WACQLQIAUWURGA-UHFFFAOYSA-N

物化性质

• 熔点：
  202-205 °C(Solv: ethanol (64-17-5); benzene (71-43-2))
• 沸点：
  488.1±45.0 °C(Predicted)
• 密度：
  1.527±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.5
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  98
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Tris(hydroxymethyl)essigsaeure 在 四氢呋喃 、 高氯酸 、 氯甲酸乙酯 、 溶剂黄146 、 三乙胺 作用下， 生成 3-acetoxy-2,2-bis-acetoxymethyl-propionic acid amide
  参考文献：
  名称：

  Heyns; Beck, Chemische Berichte, 1956, vol. 89, p. 1648,1650

  摘要：

  DOI：
• 作为产物：
  描述：

  季戊四醇 在 platinum on activated charcoal 、 水 、 氧气 作用下， 生成 Tris(hydroxymethyl)essigsaeure
  参考文献：
  名称：

  Heyns; Beck, Chemische Berichte, 1956, vol. 89, p. 1648,1650

  摘要：

  DOI：

文献信息

• [EN] IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE<br/>[FR] COMPOSÉS IMIDAZOLOTHIAZOLES UTILISÉS COMME MODULATEURS DE PROTÉINE KINASES
  申请人：AMBIT BIOSCIENCE CORP

  公开号：WO2010054058A1

  公开（公告）日：2010-05-14

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  提供了用于调节受体激酶活性以及用于治疗、预防或改善由受体激酶介导的疾病或紊乱症状的化合物、组合物和方法。
• [EN] NOVEL DERIVATIVES OF CURCUMINOIDS AND USE THEREOF AS AN ANTICANCER AGENT<br/>[FR] NOUVEAUX DÉRIVÉS DE CURCUMINOÏDES ET LEUR UTILISATION COMME AGENT ANTICANCÉREUX
  申请人：UNIV CHINA MEDICAL

  公开号：WO2017218219A1

  公开（公告）日：2017-12-21

  A series of novel bis(hydroxymethyl) alkanoate derivatives of curcuminoids were designed, and synthesized, which show anticancer activity, and in particular to breast cancer, colon cancer, and prostate cancer.

  一系列新型的双(羟甲基)烷基酸酯类姜黄素衍生物被设计和合成，表现出抗癌活性，特别是对乳腺癌、结肠癌和前列腺癌。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND PHARMACEUTICAL APPLICATION THEREOF
  申请人：NAKAI Hisao

  公开号：US20100063104A1

  公开（公告）日：2010-03-11

  It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

  本发明旨在提供一种由公式（I）表示的化合物：其中所有符号如描述中所定义的；其具有p38 MAP激酶抑制活性，其盐，其N-氧化物，其溶剂合物或其前药。本发明的化合物可用于预防或治疗疾病，其中被认为异常产生细胞因子如炎症性细胞因子或趋化因子或对它们过度反应与病理情况的发生和加重有关，换句话说，是细胞因子介导的疾病，例如炎症性疾病，呼吸系统疾病，心血管疾病，中枢神经系统疾病或类似疾病。
• Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
  申请人：Ono Pharmaceuticals Co., Ltd.

  公开号：US07968572B2

  公开（公告）日：2011-06-28

  It is intended to provide a compound represented by the formula (I): wherein all the symbols are as defined in the description; which has a p38 MAP kinase inhibitory activity, a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof. The compound of the invention is useful for preventing or treating a disease in which the abnormal production of a cytokine such as an inflammatory cytokine or a chemokine or overreaction to them is considered to be involved in the cause and aggravation of pathological conditions, in other words, an inflammatory disease, a respiratory disease, a cardiovascular disease, a central nervous system disease or the like, which is a cytokine-mediated disease.

  本发明旨在提供一种由公式（I）表示的化合物：其中所有符号如描述中所定义的；该化合物具有p38 MAP激酶抑制活性，其盐，其N-氧化物，其溶剂化物或其前药。本发明的化合物可用于预防或治疗疾病，其中细胞因子的异常产生，如炎性细胞因子或趋化因子，或对它们的过度反应被认为是病理情况的原因和恶化，换句话说，是一种细胞因子介导的疾病，如炎症性疾病，呼吸系统疾病，心血管疾病，中枢神经系统疾病或类似疾病。
• IMIDAZOLOTHIAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Apuy Julius L.

  公开号：US20120070410A1

  公开（公告）日：2012-03-22

  Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.

  本发明提供了用于调节受体激酶活性的化合物、组合物和方法，并用于治疗、预防或改善由受体激酶介导的一种或多种疾病或障碍的症状。